What is BD?
BD operates as a diversified global medical technology leader, specializing in the development and manufacturing of critical medical devices, diagnostic systems, and laboratory equipment. The company is a cornerstone of modern healthcare, providing essential tools that enhance patient safety, streamline drug delivery, and advance the field of biosciences. Through its expansive portfolio, BD supports a wide array of healthcare providers, ensuring that clinical environments are equipped with the precision instruments necessary for high-stakes diagnostics and therapeutic interventions. Its market position is defined by a deep integration into the global supply chain, where it serves as a primary partner for institutions seeking to improve patient outcomes through technological innovation.
How much funding has BD raised?
BD has raised a total of $71M across 3 funding rounds:
Stock Offering
$12M
Grant
$24M
Other Financing Round
$35M
Stock Issuance/Offering (1962): $12M, investors not publicly disclosed
Grant (2020): $24M led by U.S. Department of Defense and U.S. Department of Health and Human Services
Other Financing Round (2025): $35M, investors not publicly disclosed
Key Investors in BD
U.S. Department of Defense
A federal executive department responsible for coordinating national security and the United States Armed Forces, often providing grants for critical medical infrastructure and pandemic preparedness.
U.S. Department of Health and Human Services
The primary U.S. government agency tasked with protecting the health of all Americans and providing essential human services, frequently backing large-scale medical innovation.
Undisclosed Investor
An undisclosed institutional participant contributing to the latest strategic financing round to support the company's long-term growth objectives.
What's next for BD?
Looking ahead, the strategic deployment of the $35M will likely focus on accelerating the integration of next-generation diagnostic systems and expanding the company's footprint in high-growth bioscience markets. As BD navigates the current enterprise-level funding cycle, the focus remains on optimizing operational efficiency and scaling its drug delivery platforms to meet the demands of a post-pandemic healthcare landscape. By prioritizing R&D and infrastructure modernization, the company is well-positioned to maintain its competitive edge, ensuring that its technological advancements continue to set the standard for safety and efficacy in the medical device industry. The firm's trajectory suggests a continued emphasis on strategic partnerships and the pursuit of scalable healthcare solutions that address both immediate clinical needs and long-term systemic challenges.
See full BD company page
